REVIEW article

Front. Dement.

Sec. Cellular and Molecular Mechanisms of Dementia

Volume 4 - 2025 | doi: 10.3389/frdem.2025.1513144

This article is part of the Research TopicExploring the Link Between Neuronal Hyperexcitability and Cognitive Decline in Alzheimer’s Disease and Other DementiasView all 4 articles

Evidence that cholinergic mechanisms contribute to hyperexcitability at early stages in Alzheimer's disease

Provisionally accepted
  • Nathan S. Kline Institute for Psychiatric Research, Orangeburg, United States

The final, formatted version of the article will be published soon.

A long-standing theory for Alzheimer's disease (AD) has been that deterioration of synapses and depressed neuronal activity is a major contributing factor. We review the increasing evidence, in humans and in mouse models, that show that there is often neuronal hyperactivity at early stages rather than decreased activity. We discuss studies in mouse models showing that hyperexcitability can occur long before plaque deposition and memory impairment. In mouse models, a generator of the hyperactivity appears to be the dentate gyrus. We present evidence, based on mouse models, that inhibition of muscarinic cholinergic receptors or medial septal cholinergic neurons can prevent hyperactivity. Therefore, we hypothesize the novel idea that cholinergic neurons are overly active early in the disease, not depressed. In particular we suggest the medial septal cholinergic neurons are overly active and contribute to hyperexcitability. We further hypothesize that the high activity of cholinergic neurons at early ages ultimately leads to their decline in function later in the disease. We review the effects of a prenatal diet that increases choline, the precursor to acetylcholine and modulator of many other functions. In mouse models of AD, maternal choline supplementation (MCS) reduces medial septal cholinergic pathology, amyloid accumulation and hyperexcitability, especially in the dentate gyrus, and improves cognition.

Keywords: cholinergic, muscarinic, Memory, amyloid β, mouse model, Tg2576, Down Syndrome, Ts65Dn

Received: 17 Oct 2024; Accepted: 19 May 2025.

Copyright: © 2025 Scharfman, Kam, Duffy, LaFrancois, Leary, Chartampila, Ginsberg and Lisgaras. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Helen E Scharfman, Nathan S. Kline Institute for Psychiatric Research, Orangeburg, United States

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.